Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114218 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00114218 is a Phase 2 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 28 participants.
The verdict
NCT00114218, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving gemcitabine together with docetaxel works in treating patients with recurrent or persistent uterine cancer. Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Interventions
- DRUG Docetaxel
- DRUG Gemcitabine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2005-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00114218
The ClinicalTrials.gov registry entry for NCT00114218 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00114218 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00114218 about?
NCT00114218 is a clinical study titled "Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer". This phase II trial is studying how well giving gemcitabine together with docetaxel works in treating patients with recurrent or persistent uterine cancer. Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the c...
What is the current status of trial NCT00114218?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2005-03.
What interventions are being tested in trial NCT00114218?
The interventions under investigation include: Docetaxel (DRUG), Gemcitabine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00114218?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.